{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:33:50Z","timestamp":1791657230493,"version":"4.3.4"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>A large number of tumor types arise from the mucosa of the sinonasal cavities. Although presenting clinically distinct behavior, due to poorly differentiated histologic features, they can be difficult to classify correctly. Our aim was to investigate whether <jats:italic toggle=\"yes\">IDH2<\/jats:italic> and <jats:italic toggle=\"yes\">IDH1<\/jats:italic> mutations may be specific to a subset of undifferentiated and poorly differentiated sinonasal carcinomas. A total of 125 tumor samples of 7 different histologic subtypes were analyzed for <jats:italic toggle=\"yes\">IDH<\/jats:italic> mutations by sequencing and mutant-specific immunohistochemistry, and the results were correlated to clinical and follow-up data. The highest incidence of <jats:italic toggle=\"yes\">IDH2<\/jats:italic> mutations occurred in sinonasal undifferentiated carcinoma, with 11\/36 (31%) cases affected. However, also, 1\/9 neuroendocrine carcinomas, 2\/4 high-grade non\u2013intestinal-type adenocarcinomas, and 1\/8 poorly differentiated squamous cell carcinomas carried the <jats:italic toggle=\"yes\">IDH2<\/jats:italic> mutation, whereas 1\/48 intestinal-type adenocarcinomas harbored an <jats:italic toggle=\"yes\">IDH1<\/jats:italic> mutation. Immunohistochemical analysis of mutant IDH1\/2 produced a number of false-negative results, but also 1 false-positive tumor was found. Disease-specific survival was more favorable in <jats:italic toggle=\"yes\">IDH2<\/jats:italic>-mutant versus wild-type cases. Our data suggest that <jats:italic toggle=\"yes\">IDH<\/jats:italic>-mutant sinonasal cancers, independent of their histologic subtype, may represent a distinct tumor entity with less aggressive clinical behavior. Clinically, patients with these mutations may benefit from specific IDH-guided therapies.<\/jats:p>","DOI":"10.1097\/pas.0000000000001420","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T19:40:46Z","timestamp":1577216446000},"page":"396-405","source":"Crossref","is-referenced-by-count":60,"title":["IDH2 Mutation Analysis in Undifferentiated and Poorly Differentiated Sinonasal Carcinomas for Diagnosis and Clinical Management"],"prefix":"10.1097","volume":"44","author":[{"given":"Cristina","family":"Riobello","sequence":"first","affiliation":[{"name":"Department of Head and Neck Oncology, ISPA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"L\u00f3pez-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, ISPA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia N.","family":"Cabal","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, ISPA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Garc\u00eda-Mar\u00edn","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, ISPA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Su\u00e1rez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, ISPA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"S\u00e1nchez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Otolaryngology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Vivanco","sequence":"additional","affiliation":[{"name":"Pathology, HUCA, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Blanco","sequence":"additional","affiliation":[{"name":"Pathology, HUCA, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Otolaryngology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Franchi","sequence":"additional","affiliation":[{"name":"Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Llorente","sequence":"additional","affiliation":[{"name":"Otolaryngology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario A.","family":"Hermsen","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, ISPA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrclinonc.2014.97","article-title":"Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances","volume":"11","author":"Llorente","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ctrv.2015.07.004","article-title":"The role of systemic therapy in the management of sinonasal cancer: a critical review","volume":"41","author":"Bossi","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ctrv.2010.08.004","article-title":"Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons","volume":"37","author":"Ramaekers","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrc3659","article-title":"NUT midline carcinoma","volume":"14","author":"French","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/PAS.0b013e31827b1cd6","article-title":"Human papillomavirus-related carcinoma with adenoid cystic-like features: a peculiar variant of head and neck cancer restricted to the sinonasal tract","volume":"37","author":"Bishop","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/PAS.0000000000000797","article-title":"SMARCB1 (INI-1)-deficient sinonasal carcinoma: a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity","volume":"41","author":"Agaimy","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/path.4915","article-title":"Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas","volume":"242","author":"Dogan","year":"2017","journal-title":"J Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/modpathol.2016.239","article-title":"Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma","volume":"30","author":"Jo","year":"2017","journal-title":"Mod Pathol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/PAS.0000000000001064","article-title":"Immunohistochemical detection and molecular characterization of IDH-mutant sinonasal undifferentiated carcinomas","volume":"42","author":"Mito","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00401-018-1854-7","article-title":"DNA methylation-based reclassification of olfactory neuroblastoma","volume":"136","author":"Capper","year":"2018","journal-title":"Acta Neuropathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-5-5","article-title":"Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients","volume":"5","author":"Chotirat","year":"2012","journal-title":"J Hematol Oncol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"774","DOI":"10.18632\/oncotarget.577","article-title":"Mutant IDH1 is required for IDH1 mutated tumor cell growth","volume":"3","author":"Jin","year":"2012","journal-title":"Oncotarget"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci Transl Med"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cam4.149","article-title":"Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1","volume":"2","author":"Liu","year":"2013","journal-title":"Cancer Med"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J Pathol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J Clin Oncol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ccr.2013.04.024","article-title":"Releasing the block: setting differentiation free with mutant IDH inhibitors","volume":"23","author":"Pirozzi","year":"2013","journal-title":"Cancer Cell"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-cancerbio-050216-122051","article-title":"Targeted differentiation therapy with mutant IDH inhibitors: early experiences and parallels with other differentiation agents","volume":"1","author":"Stein","year":"2017","journal-title":"Annu Rev Cancer Biol"},{"key":"R25-20230922","first-page":"373","article-title":"Targeting isocitrate dehydrogenase (IDH) in cancer","volume":"21","author":"Fujii","year":"2016","journal-title":"Discov Med"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1038\/s41598-018-21690-6","article-title":"Genetic profiling of poorly differentiated sinonasal tumours","volume":"8","author":"L\u00f3pez-Hern\u00e1ndez","year":"2018","journal-title":"Sci Rep"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00000478-198611000-00004","article-title":"Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma","volume":"10","author":"Frierson","year":"1986","journal-title":"Am J Surg Pathol"},{"issue":"suppl 2","key":"R28-20230922","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1055\/s-0034-1390014","article-title":"Esthesioneuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma: Differentiation in diagnosis and treatment","volume":"18","author":"Su","year":"2014","journal-title":"Int Arch Otorhinolaryngol"},{"issue":"suppl 1","key":"R29-20230922","first-page":"E2259","article-title":"Neuroendocrine neoplasms of the sinonasal region","volume":"38","author":"Bell","year":"2016","journal-title":"Head Neck"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/s41379-019-0285-x","article-title":"DNA methylation-based classification of sinonasal undifferentiated carcinoma","volume":"32","author":"Dogan","year":"2019","journal-title":"Mod Pathol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1634\/theoncologist.2016-0287","article-title":"Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options","volume":"22","author":"Gay","year":"2017","journal-title":"Oncologist"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1158\/1541-7786.MCR-17-0135","article-title":"Comprehensive molecular profiling of olfactory neuroblastoma identifies potentially targetable FGFR3 amplifications","volume":"15","author":"Lazo de la Vega","year":"2017","journal-title":"Mol Cancer Res"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"811.e5","DOI":"10.1016\/j.celrep.2018.09.047","article-title":"Integrated multi-omic analysis of esthesioneuroblastomas identifies two subgroups linked to cell ontogeny","volume":"25","author":"Classe","year":"2018","journal-title":"Cell Rep"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.anndiagpath.2014.01.003","article-title":"Role of p40 and cytokeratin 5\/6 in the differential diagnosis of sinonasal undifferentiated carcinoma","volume":"18","author":"Singh","year":"2014","journal-title":"Ann Diagn Pathol"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1074\/jbc.M112.435495","article-title":"The Potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization","volume":"288","author":"Ward","year":"2013","journal-title":"J Biol Chem"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1038\/onc.2011.416","article-title":"Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production","volume":"31","author":"Ward","year":"2012","journal-title":"Oncogene"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V128.22.343.343","article-title":"Enasidenib (AG-221), a potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) Enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS)","volume":"128","author":"Stein","year":"2016","journal-title":"Blood"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.18632\/oncotarget.1412","article-title":"Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine","volume":"4","author":"Turcan","year":"2013","journal-title":"Oncotarget"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:50:42Z","timestamp":1695423042000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001420","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,23]]}}}